NCT00287118

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 189 (actual)
• Sponsor: Merck KGaA, Darmstadt, Germany · Industry
• Sex: All
• Age: 17 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

An open-label, multi-center study to establish psoriasis control of moderate to severe plaque psoriasis with Raptiva therapy administered subcutaneously for 24 weeks.

Conditions

• Candidates for Systemic Therapy for Psoriasis
• Psoriasis

Interventions

Type	Name	Description
DRUG	Efalizumab	Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.

Timeline

• Start date: 2004-10-27
• Primary completion: 2006-05-30
• Completion: 2006-05-30
• First posted: 2006-02-06
• Last updated: 2018-04-03
• Results posted: 2018-04-03

Locations

1 site across 1 country: Switzerland